{
    "id": 29055,
    "fullName": "SLFN11 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "SLFN11 over exp indicates an over expression of the Slfn11 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 91607,
        "geneSymbol": "SLFN11",
        "terms": [
            "SLFN11",
            "SLFN8/9"
        ]
    },
    "variant": "over exp",
    "createDate": "12/04/2018",
    "updateDate": "12/04/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15334,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Talzenna (talazoparib) combined with Temodar (temozolomide) resulted in a synergistic effect in MGMT-proficient leukemia cells with overexpression of SLFN11, demonstrating reduced cell viability in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30985,
                "profileName": "SLFN11 over exp"
            },
            "therapy": {
                "id": 1377,
                "therapyName": "Talazoparib + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15333,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Talzenna (talazoparib) combined with Temodar (temozolomide) resulted in a synergistic effect in MGMT-proficient prostate cancer cells with overexpression of SLFN11, demonstrating reduced cell viability in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30985,
                "profileName": "SLFN11 over exp"
            },
            "therapy": {
                "id": 1377,
                "therapyName": "Talazoparib + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15354,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VE-821 treatment combined with Lynparza (olaparib) resulted in a synergistic effect in prostate cancer cells with overexpression of SLFN11, demonstrating greater reduced cell viability compared to Lynparza (olaparib) treatment alone in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30985,
                "profileName": "SLFN11 over exp"
            },
            "therapy": {
                "id": 7563,
                "therapyName": "Olaparib + VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15351,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VE-821 treatment combined with Talzenna (talazoparib) resulted in a synergistic effect in prostate cancer cells with overexpression of SLFN11, demonstrating greater reduced cell viability compared to Talzenna (talazoparib) treatment alone in culture and increased apoptotic activity (PMID: 27708213).",
            "molecularProfile": {
                "id": 30985,
                "profileName": "SLFN11 over exp"
            },
            "therapy": {
                "id": 7562,
                "therapyName": "Talazoparib + VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15353,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VE-821 treatment combined with Talzenna (talazoparib) resulted in a synergistic effect in Ewing's sarcoma cells with overexpression of SLFN11, demonstrating greater reduced cell viability compared to Talzenna (talazoparib) treatment alone in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30985,
                "profileName": "SLFN11 over exp"
            },
            "therapy": {
                "id": 7562,
                "therapyName": "Talazoparib + VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15359,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Temodar (temozolomide) treatment resulted in reduced tumor growth in small cell lung carcinoma cell line xenograft models with overexpression of SLFN11 and high MGMT, however, to a lesser extent than when compared to the combination of Talzenna (talazoparib) and Temodar (temozolomide) (PMID: 27708213).",
            "molecularProfile": {
                "id": 30985,
                "profileName": "SLFN11 over exp"
            },
            "therapy": {
                "id": 1141,
                "therapyName": "Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15355,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VE-821 treatment combined with Lynparza (olaparib) resulted in a synergistic effect in leukemia cells with overexpression of SLFN11, demonstrating greater reduced cell viability compared to Lynparza (olaparib) treatment alone in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30985,
                "profileName": "SLFN11 over exp"
            },
            "therapy": {
                "id": 7563,
                "therapyName": "Olaparib + VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15335,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Talzenna (talazoparib) combined with Temodar (temozolomide) treatment resulted in a synergistic effect in MGMT-proficient Ewing's sarcoma cells with overexpression of SLFN11, demonstrating reduced cell viability in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30985,
                "profileName": "SLFN11 over exp"
            },
            "therapy": {
                "id": 1377,
                "therapyName": "Talazoparib + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15358,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Talzenna (talazoparib) and Temodar (temozolomide) resulted in a synergistic effect in small cell lung carcinoma cell line xenograft models with overexpression of SLFN11 and high MGMT, demonstrating a greater reduced tumor growth compared to treatment with Talzenna (talazoparib) alone (PMID: 27708213).",
            "molecularProfile": {
                "id": 30985,
                "profileName": "SLFN11 over exp"
            },
            "therapy": {
                "id": 1377,
                "therapyName": "Talazoparib + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15356,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VE-821 treatment combined with Lynparza (olaparib) resulted in a synergistic effect in Ewing's sarcoma cells with overexpression of SLFN11, demonstrating greater reduced cell viability compared to Lynparza (olaparib) treatment alone in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30985,
                "profileName": "SLFN11 over exp"
            },
            "therapy": {
                "id": 7563,
                "therapyName": "Olaparib + VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15357,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Talzenna (talazoparib) treatment resulted in reduced tumor growth in small cell lung carcinoma cell line xenograft models with overexpression of SLFN11 and high MGMT, however, to a lesser extent than when compared to the combination of Talzenna (talazoparib) and Temodar (temozolomide) (PMID: 27708213).",
            "molecularProfile": {
                "id": 30985,
                "profileName": "SLFN11 over exp"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15352,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VE-821 treatment combined with Talzenna (talazoparib) resulted in a synergistic effect in leukemia cells with overexpression of SLFN11, demonstrating greater reduced cell viability compared to Talzenna (talazoparib) treatment alone in culture and increased apoptotic activity (PMID: 27708213).",
            "molecularProfile": {
                "id": 30985,
                "profileName": "SLFN11 over exp"
            },
            "therapy": {
                "id": 7562,
                "therapyName": "Talazoparib + VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30985,
            "profileName": "SLFN11 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}